REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 161 filers reported holding REATA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.49 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,299,990 | +302.8% | 12,750 | +259.2% | 0.24% | +269.2% |
| Q1 2023 | $322,766 | -96.9% | 3,550 | -96.6% | 0.06% | -96.4% |
| Q3 2021 | $10,475,000 | -27.0% | 104,120 | +2.8% | 1.80% | -27.0% |
| Q2 2021 | $14,340,000 | +42.1% | 101,319 | +0.1% | 2.46% | +22.6% |
| Q1 2021 | $10,090,000 | -28.2% | 101,204 | -11.0% | 2.01% | -25.4% |
| Q4 2020 | $14,055,000 | +44.8% | 113,692 | +14.1% | 2.69% | +27.9% |
| Q3 2020 | $9,708,000 | -37.5% | 99,652 | +0.1% | 2.10% | -46.4% |
| Q2 2020 | $15,540,000 | +22.9% | 99,602 | +13.7% | 3.92% | -6.3% |
| Q1 2020 | $12,640,000 | -31.4% | 87,572 | -2.8% | 4.19% | -1.5% |
| Q4 2019 | $18,426,000 | +212.0% | 90,135 | +22.5% | 4.25% | +181.8% |
| Q3 2019 | $5,906,000 | -14.4% | 73,555 | +0.6% | 1.51% | -7.7% |
| Q2 2019 | $6,896,000 | – | 73,090 | – | 1.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |